- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06092008
Performance of New Diagnostic Methods in Older Adults With Pneumonia (PNEUMO)
February 5, 2026 updated by: Katherine Buck, Ohio State University
Establishing and Implementing Pneumonia Diagnosis in ED Older Adults: A Mixed Methods Approach
Create a clinical diagnostic pathway for older ED adults with pneumonia and its subgroups (bacterial, viral, and co-infection) and determine whether novel biomarkers improve diagnostic accuracy.
The investigators will conduct a prospective observational trial of 250 ED patients ≥65 years old with suspected pneumonia.
The investigators will perform analyses overall and by subgroups, seeking common models to ease adoption.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael Hill, RN
- Phone Number: 614-293-6185
- Email: michael.hill@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University
-
Contact:
- Katherine Buck, MD, MPH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adults aged 65 and older presenting to the Emergency Department
Description
Inclusion Criteria:
- Adults aged 65 and older presenting to the ED with suspected pneumonia defined as (1) either a physician order for CXR OR CT OR a chief complaint consistent with dyspnea; AND (2) physician suspicion of pneumonia prior to ED testing (score of 2-5 on Likert scale)
Exclusion Criteria:
- inability to obtain consent from the patient or an LAR
- active cancer
- organ transplant
- immunosuppression
- trauma activation
- suicidal ideation
- incarceration
- antibiotics in the last 14 days
- a separate episode of lower respiratory illness in the last 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pneumonia
Time Frame: 3 years
|
Presence or absence of pneumonia based on adjudicator review of chart.
The goal of the study is to create a diagnostic pathway for pneumonia in older adult emergency department patients.
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 2, 2022
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
June 30, 2027
Study Registration Dates
First Submitted
October 11, 2023
First Submitted That Met QC Criteria
October 17, 2023
First Posted (Actual)
October 23, 2023
Study Record Updates
Last Update Posted (Actual)
February 6, 2026
Last Update Submitted That Met QC Criteria
February 5, 2026
Last Verified
February 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022H0136
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Khyber Teaching HospitalNot yet recruitingCommunity Acquired Pneumonia | Childhood PneumoniaPakistan
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityWithdrawnHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Universidad de la SabanaClínica Universidad de La Sabana; Universidad de La Sabana, ColombiaCompletedPneumococcal Pneumonia | Community Acquired Pneumonia (CAP)Colombia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
Hu YinanEnrolling by invitationSialic Acid | Superoxide Dismutase | Lipid PneumoniaChina